"Black box" warning needed for Flomax before cataract surgery?
This article was originally published in Scrip
Executive Summary
Experts have called for stronger warnings for patients receiving Boehringer Ingelheim's benign prostatic hyperplasia (BPH) treatment Flomax (tamsulosin) when they are undergoing cataract surgery, as it has been found to increase the risk of serious postoperative ophthalmic adverse events, including intra-operative floppy iris syndrome (IFIS).